Clinical Trials in Denver

Showing 13421-13440 of 15,604 trials

Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression

NCT02178683

This protocol will evaluate Tacrolimus and MMF after conditioning with fludarabine and low-dose TBI in patients who are not candidates for conventional allografting. A novel approach to immunosuppression will be tested incorporating an early but extended taper of Tacrolimus starting on day +80 or in the case of relapse. The goal is to induce early immunity and GVT effects without compromising GVHD control. The anti-metabolite MMF will be re-introduced on day +100 to try and induce tolerance and block chronic GVHD during the taper of the Tacrolimus. DLI may be given in the presence of disease progression but not for mixed chimerism as in previous protocols.

Graft Versus Host Disease

Colorado Blood Cancer Institute50 participantsStarted Nov 2010

Denver, Colorado, United States

COMPLETEDPhase 2< 1 mile

Dose Range Finding Study of Fedovapagon in Men With Nocturia

NCT01656239

The purpose of this study is to determine the dose level(s) of fedovapagon which result in a decrease in the mean nocturnal void frequency.

Nocturia

Vantia Ltd358 participantsStarted Aug 2012

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Mobile, Alabama, United States +53 more locations

Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression

Dose Range Finding Study of Fedovapagon in Men With Nocturia

Find Trials by Condition in Denver

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

Non-traditional Cardiovascular Risk Factors and Atherosclerosis in Type 2 Diabetes

Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT Device

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

Ondansetron and the QT Interval In Adult Emergency Department Patients

Minimally-Invasive Cardiovascular Hemodynamic Optimization (MiCHO) Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock

MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma